Compare DexCom, Inc. (DXCM) vs SpaceX (SPCX) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

SPCX stock trades at $131.53, down 3.34% and below its $135 IPO price, with bearish technical signals dominating. The company shows aggressive growth spending with $19.6B in capital expenditures in 2025, resulting in a net loss of $4.94B despite $18.67B revenue. Valuation metrics remain elevated with P/S of 91.64 and EV/EBITDA of 951.8, while profitability metrics show negative ROE of -25.46% and net margin of -45%.

Despite analyst consensus maintaining a buy rating with $237.78 price target, the stock faces significant execution risks from capital-intensive expansion and widening losses. The recent decline below IPO price tests investor confidence in SpaceX's ability to transition from growth spending to profitability, with 2026 projections showing further losses expanding to $8.7B.